Fresenius Invests in BioIntellisense AI Platform
“We made this strategic investment in BioIntelliSense to enable our medical staff to more efficiently and effectively continuously monitor patients, facilitating precise and timely interventions and reducing cost to the system,” explains FMCNA CEO, Bill Valle.
Read the full article » | Posted 09-12-2019
- Nephrologists: Sign Up for Home Dialysis University in February or March Posted 02-07-2024
- Minimally-invasive Hernia Repair for PD Posted 01-17-2024
- Quanta Machine is Safe and Effective Posted 01-17-2024
- Baxter Empowers has Tools for Healthcare Professionals Posted 11-15-2023